Effect of Hepatic Hyperthermia on Plasma Concentration-Time Curve of Pirarubicin after Hepatic Arterial Infusion in Patients with Primary or Secondary Liver Cancer
スポンサーリンク
概要
- 論文の詳細を見る
Intravenous plasma concentration-time curve and AUC of pirarubicin, which is metabolized mainly in the liver, infused in the hepatic artery with or without hyperthermia is compared. One patient with hepatocellular carcinoma and 4 cases with metastatic liver cancer were enrolled. Pirarubicin (THP-ADR) (15mg/m<SUP>2</SUP>) was infused in proper hepatic artery in 20 minutes from implanted catheter. Intravenous plasma concentration of the drug was measured immediately after injection, 0.5, 1, 3 and 6 hours after injection respectively. Three weeks later, the same amount of the drug was injected to the same patient concomitantly with hyperthermic treatment of the liver using Thermotron RF8 and the drug concentration was measured. Changes of WBC, platelets counts, total bilirubin and AST (GOT) after pirarubicin injection with or without hyperthermia were also compared. Mean value of AUC (HR×μg/ml) of the injected pirarubicin without and with hyperthermia were 0.068+/-0.022 and 0.062+/-0.023 respectively. No significant difference of AUC between hepatic injection alone and injection during hyperthermia was seen by paired <I>t</I>-test (p=0.563). No significant difference was seen in WBC, platelets counts, total bilirubin and AST between pirarubicin injection with and without hyperthermia. It was suggested that toxicity of pirarubicin injected in hepatic artery would not increase even if combined with hyperthemic treatment of the liver.
- 日本ハイパーサーミア学会の論文
日本ハイパーサーミア学会 | 論文
- わが国における温熱療法のあゆみと現状:2004年のアンケート調査
- 癌治療における併用療法としての低温度温熱処置の有用性について
- The Biology of Heat-induced DNA Double-Strand Breaks
- 良好な生存率を示した非小細胞肺癌の化学療法とハイパーサーミアの併用療法
- 温熱感受性ならびに温熱効果の修飾について